Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
Kirti Desai 67 Chief Financial Officer Dr. Neal Flomenberg 70 Chief Scientific Officer and Global R&D Lead Sadiq Khan 62 Chief Commercial Officer Non-Employee Directors Surendra Ajjarapu 54 Director Jeffrey Feike 74 Director Dr. Keow Lin Goh 52 Director Dr. Curtis Patton 89 Director Susan Podlogar 60 Director Victor Sordillo 71 Director Executive Officers Dr. Ryan Saadi , 59, has served as our Chief Executive Officer and Chairperson since February 14, 2024, and served as Chief Executive Officer and Chairperson of Tevogen Bio beginning in June 2020. Dr. Saadi has been a member of the Leadership Council of the Yale School of Public Health since 2021. Prior to founding Tevogen Bio, Dr. Saadi was the Global Vice President of Evidence, Market Access, and Strategic Pricing for CSL Behring, a biopharmaceutical company that manufactures plasma-derived and recombination therapeutic products, from September 2018 to October 2019. Before CSL Behring, Dr.
This record is keyed to SEC CIK 0002011765 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 44 institutional-holder rows on these vehicles, under 22 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.